About InfeXtious Therapeutic

Antiviral, Antibiotic, Antifungal

Infextious Therapeutic is an AJK Biopharmaceutical company founded in 2018. Its mission is combating the life–threatening infectious disease using a novel Cyclic Peptide platform. Its focus is on the clinical development of novel anti-infective therapeutic drugs with emphasis on developing antiviral peptides against SARS-COV2, herpes simplex (HSV), and human papilloma (HPV) viruses, Broad-spectrum antimicrobial peptides with activity against multi-drug resistant bacteria, and Antifungal peptides against Onychomycosis.

According to the U.S. Center for Disease Control and Prevention, an increasing number of bacterial have become resistant to currently available antibiotics.

According to the CDC's Antibiotic Threat Report, the total estimated financial cost of the antibiotic resistance to the U.S may exceed as high as $20 billion in excess direct healthcare cost and additional social cost for the lost productivity as high as $35 billion a year.

History

Infextious Therapeutic is an AJK Biopharmaceutical company founded in 2018. Its mission is combating the life–threatening infectious disease using a novel Cyclic Peptide platform. Its focus is on the clinical development of a novel anti-infective therapeutic drugs with emphasis on developing.

Antiviral peptides against SARS-COV2, herpes simplex (HSV) and human papilloma (HPV) viruses Broad-spectrum antimicrobial peptides with activity against multi-drug resistant bacteria Antifungal peptides against Onychomycosis.


Mission

Our mission is to introduce a new class of compounds to eradicate the infectious diseases and generate drugs that are active against the antibiotic, antiviral, and antifungal-resistant infections.

To provide value proposition to both patient and healthcare providers to lower the hospitalization and mortality rate.


Cal. Civ. Code § 1798.102 - Do Not Sell My Personal Information